Coherus BioSciences Inc (CHRS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Coherus BioSciences Inc (CHRS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH410367D
  • |
  • Pages: 61
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Coherus BioSciences Inc (Coherus) is a biosimilar platform company that develops and commercializes biosimilar drugs. The company's pipeline product candidates include CHS-1701, an pegfilgrastim used to treat febrile neutropenia; CHS-0214, is an etanercept biosimilar candidate which is used for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriasis, psoriasis arthritis and rheumatoid arthritis; and CHS-1420, is a adalimumab biosimilar candidate,which is being developed to treat crohn's disease, ulcerative colitis, and psoriasis arthritis, among others. Coherus capabilities includes process science, analytical characterization, protein production and clinical-regulatory development. The company develops drugs in collaboration with other organizations. Coherus is headquartered in Redwood City, California, the US.

Coherus BioSciences Inc (CHRS)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note : Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Coherus BioSciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Coherus BioSciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Coherus BioSciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Coherus BioSciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Coherus BioSciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Coherus BioSciences Inc, Pharmaceuticals & Healthcare, Deal Details 12

Venture Financing 12

Coherus BioSciences Raises USD55 Million in Series C Venture Financing 12

Coherus BioSciences Raises USD 28 Million In Venture Financing 14

Coherus BioSciences Raises USD 46.3 Million In Venture Financing 15

Partnerships 16

Baxter Amends Co-Development Agreement with Coherus Biosciences 16

Licensing Agreements 17

Coherus BioSciences Enters into Licensing Agreement with Genentech 17

Orox Pharma Enters into Licensing Agreement with Coherus BioSciences 18

Equity Offering 19

Coherus Biosciences Prices Public Offering of Shares for USD75 Million 19

Coherus BioSciences Plans to Raise up to USD8.4 Million in Public Offering of Shares 21

Coherus Biosciences Raises USD6.8 Million in Private Placement of Shares 22

Coherus BioSciences Files Registration Statement to Raise Funds through Public Offering of Shares 23

Coherus BioSciences to Raise USD75 Million in Private Placement of Shares 24

Coherus Biosciences Prices Public Offering of Shares for USD125 Million 26

Coherus Biosciences Raises USD60.8 Million in Public Offering of Shares 28

Coherus BioSciences Prices Public Offering of Shares for USD63 Million 30

Coherus BioSciences Raises USD10 Million in Private Placement of Shares 31

Coherus BioSciences Prices Public Offering of Shares for USD120 Million 32

Coherus BioSciences Raises USD92 Million in IPO of Shares 34

Coherus BioSciences Raises USD2.5 Million in Private Placement of Shares 36

Debt Offering 37

Coherus BioSciences Raises USD100 Million in Private Placement of 8.2% Notes Due 2022 37

Acquisition 39

Coherus BioSciences Acquires InteKrin Therapeutics for USD5 Million 39

Coherus BioSciences Inc-Key Competitors 40

Coherus BioSciences Inc-Key Employees 41

Coherus BioSciences Inc-Locations And Subsidiaries 42

Head Office 42

Other Locations & Subsidiaries 42

Recent Developments 43

Financial Announcements 43

Aug 08, 2018: Coherus BioSciences reports corporate highlights and second quarter 2018 financial results 43

May 10, 2018: Coherus BioSciences Reports Corporate Highlights and First Quarter 2018 Financial Results 44

Mar 08, 2018: Coherus BioSciences Announces Fourth Quarter and Full Year 2017 Financial Results 45

Nov 06, 2017: Coherus BioSciences Reports Third Quarter 2017 Operating and Financial Results 46

Aug 07, 2017: Coherus BioSciences Reports Second Quarter 2017 Corporate Highlights and Financial Results 48

May 08, 2017: Coherus BioSciences Reports First Quarter 2017 Corporate Highlights and Financial Results 50

Mar 13, 2017: Coherus BioSciences Reports Fourth Quarter and Full Year 2016 Corporate Highlights and Financial Results 52

Corporate Communications 54

May 10, 2018: Coherus BioSciences Appoints Samuel Nussbaum to Board of Directors 54

Mar 27, 2017: Coherus BioSciences Appoints Erik Wiberg as Executive Vice President of Corporate Development 55

Legal and Regulatory 56

Mar 06, 2017: Coherus Addresses Trade Secret Action Filed by Amgen 56

Product News 57

07/27/2018: Coherus BioSciences receives positive CHMP opinion for UDENYCA (Pegfilgrastim Biosimilar Candidate) 57

Product Approvals 58

May 14, 2018: U.S. Food and Drug Administration Accepts and Acknowledges Coherus BioSciences Biologics License Application of CHS-1701 (Pegfilgrastim Biosimilar Candidate) for Review 58

May 03, 2018: Coherus BioSciences Re-Submits Biologics License Application for CHS-1701 (Pegfilgrastim Biosimilar Candidate) 59

Jun 12, 2017: Coherus Biosciences Receives Complete Response Letter From FDA for Its Biologics License Application for CHS-1701 (Pegfilgrastim Biosimilar Candidate) 60

Appendix 61

Methodology 61

About GlobalData 61

Contact Us 61

Disclaimer 61

List of Figures

Coherus BioSciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Coherus BioSciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Coherus BioSciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Coherus BioSciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Coherus BioSciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Coherus BioSciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Coherus BioSciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Coherus BioSciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

List of Tables

Coherus BioSciences Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Coherus BioSciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Coherus BioSciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Coherus BioSciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Coherus BioSciences Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Coherus BioSciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Coherus BioSciences Raises USD55 Million in Series C Venture Financing 12

Coherus BioSciences Raises USD 28 Million In Venture Financing 14

Coherus BioSciences Raises USD 46.3 Million In Venture Financing 15

Baxter Amends Co-Development Agreement with Coherus Biosciences 16

Coherus BioSciences Enters into Licensing Agreement with Genentech 17

Orox Pharma Enters into Licensing Agreement with Coherus BioSciences 18

Coherus Biosciences Prices Public Offering of Shares for USD75 Million 19

Coherus BioSciences Plans to Raise up to USD8.4 Million in Public Offering of Shares 21

Coherus Biosciences Raises USD6.8 Million in Private Placement of Shares 22

Coherus BioSciences Files Registration Statement to Raise Funds through Public Offering of Shares 23

Coherus BioSciences to Raise USD75 Million in Private Placement of Shares 24

Coherus Biosciences Prices Public Offering of Shares for USD125 Million 26

Coherus Biosciences Raises USD60.8 Million in Public Offering of Shares 28

Coherus BioSciences Prices Public Offering of Shares for USD63 Million 30

Coherus BioSciences Raises USD10 Million in Private Placement of Shares 31

Coherus BioSciences Prices Public Offering of Shares for USD120 Million 32

Coherus BioSciences Raises USD92 Million in IPO of Shares 34

Coherus BioSciences Raises USD2.5 Million in Private Placement of Shares 36

Coherus BioSciences Raises USD100 Million in Private Placement of 8.2% Notes Due 2022 37

Coherus BioSciences Acquires InteKrin Therapeutics for USD5 Million 39

Coherus BioSciences Inc, Key Competitors 40

Coherus BioSciences Inc, Key Employees 41

Coherus BioSciences Inc, Subsidiaries 42

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Coherus BioSciences Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 18225
Site License
USD 500 INR 36450
Corporate User License
USD 750 INR 54675

NEWSLETTER BY CATEGORY




Testimonials

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com